Medpace (MEDP) Beats Q4 Earnings and Revenue Estimates

Company Performance - Medpace reported quarterly earnings of $3.67 per share, exceeding the Zacks Consensus Estimate of $2.97 per share, and up from $2.46 per share a year ago, representing an earnings surprise of 23.57% [1] - The company posted revenues of $536.59 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.04%, and an increase from $498.4 million year-over-year [2] - Over the last four quarters, Medpace has surpassed consensus EPS estimates four times, but has only topped consensus revenue estimates once [2] Stock Outlook - Medpace shares have increased approximately 6.6% since the beginning of the year, outperforming the S&P 500's gain of 2.5% [3] - The current consensus EPS estimate for the upcoming quarter is $2.95 on revenues of $539.1 million, and for the current fiscal year, it is $12.42 on revenues of $2.21 billion [7] - The estimate revisions trend for Medpace is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical Services industry, to which Medpace belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of Medpace's stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]